Obesity is included in the definition of metabolic syndrome. However, there are many controversies surrounding the evaluation of obesity such as body mass index (BMI) and waist circumference (WC) in the definition of ...Obesity is included in the definition of metabolic syndrome. However, there are many controversies surrounding the evaluation of obesity such as body mass index (BMI) and waist circumference (WC) in the definition of metabolic syndrome among various populations. To understand precisely how various anthropometric indices of obesity influence metabolic parameters, we studied the correlations of BMI, WC (Japanese criteria), WC (IDF criteria), visceral fat area (VFA), subcutaneous fat area (SFA) and the VFA/SFA ratio with metabolic parameters in patients with type 2 diabetes. The influences of BMI and WC on diastolic blood pressure and HDL-cholesterol were larger than VFA, whereas the influences of visceral fat area on triglyceride, very low-density lipoprotein-cholesterol, C-peptide and high-sensitivity C-reactive protein were larger than BMI and WC. WC (IDF) was the strongest determinant of adiponectin among anthropometric indices. Present study showed significant different associations of BMI, Japan- and IDF-defined WC, VFA, SFA and the VFA/SFA ratio with blood pressure, glucose and lipid metabolism, and adipocytokines in Japanese patients with type 2 diabetes.展开更多
We investigated the relationship among delta (delta represents changes in parameters) visceral fat area, waist circumference and body weight in Japanese freshmen students. Visceral fat was measured at the umbilical le...We investigated the relationship among delta (delta represents changes in parameters) visceral fat area, waist circumference and body weight in Japanese freshmen students. Visceral fat was measured at the umbilical level using computerized tomography scanning at baseline study and 6 months later. Body weight and height, as well as waist circumference were also measured. We found that visceral fat area, waist circumference, and body weight significantly correlated with each other at baseline, and 6 months later, delta visceral fat area and changes in % visceral fat area significantly correlated with delta waist circumference and delta body weight in female and in total subjects. In addition, based on the predictive linear equations from the regression analysis, we found that 1kg of delta body weight corresponded to 0.83 cm of delta waist circumference, and 1kg of delta body weight and 1cm of delta waist circumference corresponded to 9.41% and 7.80% of changes in visceral fat area, respectively, in total subjects. The present results suggest that delta visceral fat area is closely related to delta body weight and delta waist circumference in Japanese freshmen students.展开更多
目的探讨聚乙二醇洛塞那肽对肥胖2型糖尿病患者体质量、腰围和内脏脂肪面积(VFA)的影响。方法选择肥胖2型糖尿病患者90例,随机分为洛塞那肽组60例、二甲双胍组30例。洛塞那肽组予聚乙二醇洛塞那肽皮下注射,二甲双胍组予二甲双胍口服,两...目的探讨聚乙二醇洛塞那肽对肥胖2型糖尿病患者体质量、腰围和内脏脂肪面积(VFA)的影响。方法选择肥胖2型糖尿病患者90例,随机分为洛塞那肽组60例、二甲双胍组30例。洛塞那肽组予聚乙二醇洛塞那肽皮下注射,二甲双胍组予二甲双胍口服,两组均连续治疗8周。比较两组治疗前与治疗8周体质量、腰围、BMI、VFA、FPG、2 h PG、HbA1c、血脂(TC、TG、HDL-C、LDL-C)、肝功能(ALT、AST),以及治疗期间胃肠道不良反应情况。结果洛塞那肽组治疗后体质量、腰围、BMI、VFA较治疗前明显降低(P均<0.05);二甲双胍组治疗后体质量、腰围、BMI较治疗前明显降低(P均<0.05),而VFA与治疗前比较P>0.05;洛塞那肽组体质量、腰围、BMI和VFA降幅较二甲双胍组更明显(P均<0.05)。两组治疗后FPG、2 h PG、HbA1c较治疗前均明显降低(P均<0.05),但两组FPG、2 h PG、HbA1c降幅比较P均>0.05。洛塞那肽组治疗后TC、TG、HDL-C、LDL-C、ALT、AST较治疗前明显降低(P均<0.05);二甲双胍组治疗后HDL-C较治疗前明显降低(P<0.05),而TC、TG、LDL-C、ALT、AST与治疗前比较P均>0.05;洛塞那肽组TC、TG、LDL-C、ALT、AST降幅较二甲双胍组更明显(P均<0.05),而HDL-C降幅与二甲双胍组比较P>0.05。两组治疗期间不良反应发生率比较P>0.05。结论聚乙二醇洛塞那肽能够显著降低肥胖2型糖尿病患者体质量、腰围和VFA,其效果优于二甲双胍。展开更多
文摘Obesity is included in the definition of metabolic syndrome. However, there are many controversies surrounding the evaluation of obesity such as body mass index (BMI) and waist circumference (WC) in the definition of metabolic syndrome among various populations. To understand precisely how various anthropometric indices of obesity influence metabolic parameters, we studied the correlations of BMI, WC (Japanese criteria), WC (IDF criteria), visceral fat area (VFA), subcutaneous fat area (SFA) and the VFA/SFA ratio with metabolic parameters in patients with type 2 diabetes. The influences of BMI and WC on diastolic blood pressure and HDL-cholesterol were larger than VFA, whereas the influences of visceral fat area on triglyceride, very low-density lipoprotein-cholesterol, C-peptide and high-sensitivity C-reactive protein were larger than BMI and WC. WC (IDF) was the strongest determinant of adiponectin among anthropometric indices. Present study showed significant different associations of BMI, Japan- and IDF-defined WC, VFA, SFA and the VFA/SFA ratio with blood pressure, glucose and lipid metabolism, and adipocytokines in Japanese patients with type 2 diabetes.
文摘We investigated the relationship among delta (delta represents changes in parameters) visceral fat area, waist circumference and body weight in Japanese freshmen students. Visceral fat was measured at the umbilical level using computerized tomography scanning at baseline study and 6 months later. Body weight and height, as well as waist circumference were also measured. We found that visceral fat area, waist circumference, and body weight significantly correlated with each other at baseline, and 6 months later, delta visceral fat area and changes in % visceral fat area significantly correlated with delta waist circumference and delta body weight in female and in total subjects. In addition, based on the predictive linear equations from the regression analysis, we found that 1kg of delta body weight corresponded to 0.83 cm of delta waist circumference, and 1kg of delta body weight and 1cm of delta waist circumference corresponded to 9.41% and 7.80% of changes in visceral fat area, respectively, in total subjects. The present results suggest that delta visceral fat area is closely related to delta body weight and delta waist circumference in Japanese freshmen students.
文摘目的探讨聚乙二醇洛塞那肽对肥胖2型糖尿病患者体质量、腰围和内脏脂肪面积(VFA)的影响。方法选择肥胖2型糖尿病患者90例,随机分为洛塞那肽组60例、二甲双胍组30例。洛塞那肽组予聚乙二醇洛塞那肽皮下注射,二甲双胍组予二甲双胍口服,两组均连续治疗8周。比较两组治疗前与治疗8周体质量、腰围、BMI、VFA、FPG、2 h PG、HbA1c、血脂(TC、TG、HDL-C、LDL-C)、肝功能(ALT、AST),以及治疗期间胃肠道不良反应情况。结果洛塞那肽组治疗后体质量、腰围、BMI、VFA较治疗前明显降低(P均<0.05);二甲双胍组治疗后体质量、腰围、BMI较治疗前明显降低(P均<0.05),而VFA与治疗前比较P>0.05;洛塞那肽组体质量、腰围、BMI和VFA降幅较二甲双胍组更明显(P均<0.05)。两组治疗后FPG、2 h PG、HbA1c较治疗前均明显降低(P均<0.05),但两组FPG、2 h PG、HbA1c降幅比较P均>0.05。洛塞那肽组治疗后TC、TG、HDL-C、LDL-C、ALT、AST较治疗前明显降低(P均<0.05);二甲双胍组治疗后HDL-C较治疗前明显降低(P<0.05),而TC、TG、LDL-C、ALT、AST与治疗前比较P均>0.05;洛塞那肽组TC、TG、LDL-C、ALT、AST降幅较二甲双胍组更明显(P均<0.05),而HDL-C降幅与二甲双胍组比较P>0.05。两组治疗期间不良反应发生率比较P>0.05。结论聚乙二醇洛塞那肽能够显著降低肥胖2型糖尿病患者体质量、腰围和VFA,其效果优于二甲双胍。
